Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071337 | 1.00 | BLM (0.30) | BLMPMP22HSD17B10 | |
| SCHEMBL21070131 | 0.83 | BLM (0.32) | BLMPMP22HSD17B10 | |
| SCHEMBL21069436 | 0.83 | BLM (0.32) | BLMPMP22HSD17B10 | |
| SCHEMBL560809 | 0.79 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL1903387 | 0.79 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL17841938 | 0.79 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL21070097 | 0.78 | — | — | |
| SCHEMBL21071401 | 0.78 | — | — | |
| SCHEMBL21069606 | 0.78 | — | — | |
| SCHEMBL17183915 | 0.77 | BLM (0.34) | BLMPMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | BLM 1432/4885PMP22 3827/4885HSD17B10 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.